Key result
Low-dose combination therapy lowers short-term SBP by ~15 mmHg vs placebo and ~6 mmHg vs standard care.
Why the study?
Poor adherence to multidrug regimens remains a major hurdle in managing hypertension, and low-dose combination therapy using three or more agents at half or less of the standard dose may offer greater efficacy and fewer side effects.
Does low-dose combination therapy (≥3 agents at ≤50% standard dose) improve systolic blood pressure reduction and blood pressure control compared to placebo or standard of care in adults with hypertension?
Meta-Analysis (n=5,049)
Does low-dose combination therapy (≥3 agents at ≤50% standard dose) improve systolic blood pressure reduction and blood pressure control compared to placebo or standard of care in adults with hypertension?
Low-dose combination therapy with three or more antihypertensive agents significantly improves blood pressure reduction and control rates compared to standard of care or placebo, with only a modest increase in dizziness.
Answers are grounded in this paper and cite their sources.
Supports low-dose multi-agent combinations for hypertension control; extends RCT evidence to regimens with ≥3 agents at ≤50% doses.
Background: Poor adherence to multidrug regimens is still a major hurdle in the management of hypertension. A low-dose combination therapy (LDC)in which three or more hypertensives, at half or less of the standard dose, are used can provide more efficacy and less side effects. This meta-analysis compared the efficacy and safety of LDC therapy versus placebo and standard of care (SOC). Methods: We systematically searched PubMed, Web of Science, ClinicalTrials.gov, and CENTRAL from inception to October 23, 2025, for randomized controlled trials evaluating fixed or flexible LDC (≥3 agents, each ≤50% standard dose) in adults with hypertension. Comparators included placebo, SOC, or standard-dose monotherapy. Primary outcome was mean systolic blood pressure (SBP) reduction at short-term (4-12 weeks) and long-term (6-12 months) follow-up. Secondary outcomes included blood pressure control (<140/90 mmHg) and adverse events. Results: Twelve RCTs having 5,049 hypertensive patients (baseline SBP 133-162 mmHg; 39-100% treatment-naïve or uncontrolled) were included. Compared with placebo LDC significantly reduced SBP at 4-12 weeks (mean difference [MD] -14.97 mmHg (-19.27, -10.68; I 2 =88%). Compared with SOC or monotherapy, LDC reduced SBP at 4-12 weeks (MD -6.18 [7.72, -4.64; I 2 =82%) and at 6 months (MD 6.58 mmHg [ -9.27, -3.90; I 2 =36%). LDC significantly improved the proportion of patients achieving BP <140/90 mmHg versus placebo (risk ratio [RR]=2.18, [1.67, 2.85; I 2 =23%]) and versus SOC (RR=1.37, [1.18-1.59]), an effect sustained at 6 months (RR=1.18 [1.10-1.27]). Diastolic BP reduction similarly favored LDC (-13.21 mmHg vs. SOC; -11.74 mmHg vs. placebo). Most adverse events were similar between groups; the only adverse event significantly increased with LDC was dizziness (RR=1.34 [1.02-1.75]). Conclusions: Low-dose combination treatment led to much better reductions in blood pressure and improved control rates as compared to placebo or standard care having a favorable safety profile with only dizziness being the side effect reported with a modest increase.
No takes yet. Share an insight, caveat, or question.
khan et al. (2026) conducted a meta-analysis in Hypertension (n=5,049). Low-dose combination therapy (≥3 antihypertensive agents) vs. Placebo, standard of care, or standard-dose monotherapy was evaluated on Mean systolic blood pressure (SBP) reduction at short-term (4-12 weeks) and long-term (6-12 months) follow-up (MD -14.97 mmHg (vs placebo at 4-12 weeks); MD -6.18 mmHg (vs SOC at 4-12 weeks); MD -6.58 mmHg (vs SOC at 6 months), 95% CI -19.27 to -10.68). Low-dose combination therapy significantly reduced short-term SBP versus placebo (MD -14.97 mmHg; 95% CI -19.27 to -10.68) and standard care (MD -6.18 mmHg; 95% CI -7.72 to -4.64).
Synapse has enriched 10 related papers. Consider them for comparative context: